Long-term continuous subcutaneous insulin infusion (CSII) and cardiovascular complications: Higher fractional use is not biased by risk factors

Diabetes Metab Res Rev. 2020 Jul;36(5):e3306. doi: 10.1002/dmrr.3306. Epub 2020 Mar 25.

Authors

Claudio Tubili¹, Maria Rosaria Nardone¹, Daniela Pollakova¹, Ugo Di Folco¹

Affiliation

¹ Diabetes Unit, "S. Camillo-Forlanini" Hospital, Rome, Italy.

PMID: 32129928
DOI: 10.1002/dmrr.3306

No abstract available

Publication types

Letter

MeSH terms

Cardiovascular Diseases / etiology
Cardiovascular Diseases / pathology
Cardiovascular Diseases / prevention & control*
Diabetes Mellitus, Type 1 / complications
Diabetes Mellitus, Type 1 / drug therapy*
Humans
Hypoglycemic Agents / administration & dosage*
Injections, Subcutaneous
Insulin / administration & dosage*
Insulin Infusion Systems
Prognosis
Risk Factors

Substances

Hypoglycemic Agents
Insulin